Medscript

Saxenda: uses, dosage and side effects

Saxenda contains liraglutide 3 mg and is a GLP-1 receptor agonist licensed for weight management in obesity, and in overweight where a weight-related condition is present. It is a daily injection under the skin and is prescription-only in Ireland. This page explains how it works, how it is dosed, its side effects, and what the medical assessment involves.

What Saxenda is used for

Saxenda is used for weight management alongside a reduced-calorie diet and increased physical activity, in adults with obesity and in adults who are overweight and also have a weight-related condition such as prediabetes, type 2 diabetes, high blood pressure, abnormal blood lipids or obstructive sleep apnoea. It is also licensed for adolescents in defined circumstances, which is a specialist decision. Liraglutide mimics GLP-1, a hormone the gut releases after eating: it increases the feeling of fullness, slows how quickly the stomach empties and reduces appetite, so people eat less without the constant effort of resisting hunger. It is a treatment for a chronic condition rather than a course with an end point, and weight regain after stopping is expected unless the eating and activity changes are maintained. The same active substance at lower doses is licensed under a different name for type 2 diabetes.

Side effects of Saxenda

The side effects listed in the product information are mostly digestive: nausea, vomiting, diarrhoea, constipation, indigestion, abdominal pain and reduced appetite, together with headache, tiredness, dizziness and reactions at the injection site. Nausea is most pronounced when the dose is being increased and tends to settle. Gallstones are listed as a common reaction and rapid weight loss makes them more likely; gallbladder inflammation and inflammation of the pancreas are less common but serious, as is dehydration with an effect on the kidneys when vomiting or diarrhoea is severe. Stop the injection and seek urgent medical help for severe, persistent abdominal pain that may spread to the back and comes with vomiting, which can indicate pancreatitis, and for swelling of the face or throat or difficulty breathing. Increased heart rate can occur. Suspected reactions can be reported to the HPRA.

Dosage and how to use Saxenda

Saxenda is injected under the skin of the abdomen, thigh or upper arm once a day, at any time of day but at roughly the same hour, with or without food. Treatment starts at 0.6 mg daily and the dose is increased in steps of 0.6 mg at weekly intervals up to 3.0 mg daily, and that step-by-step escalation exists to reduce nausea, so it is not shortened to reach the target faster. If a step is not tolerated, the prescriber may hold it longer or reconsider treatment. Injection sites are rotated to avoid lumps under the skin. Pens are stored in a refrigerator before first use and, once started, kept as the leaflet directs; never freeze the pen and never share it, even with a new needle. If you miss a dose, take the next one as usual and do not double up. Treatment is reviewed against the weight response, and the product information sets a stopping rule: if at least 5% of the starting body weight has not been lost after twelve weeks on 3.0 mg a day, treatment is discontinued rather than carried on unchanged.

Is Saxenda prescription-only in Ireland?

Yes. Saxenda is a prescription-only medicine in Ireland and is dispensed only against a valid prescription. Buying an injectable GLP-1 product from a website that ships without a prescription is a genuine hazard rather than a technicality: falsified pens containing the wrong substance or no active substance at all have been seized across Europe, and regulators including the HPRA have warned about them. A pharmacy in Ireland will not supply Saxenda without a prescription, and the medicine also needs a prescriber to check that obesity is the right diagnosis, that thyroid, pancreatic and gallbladder history do not rule it out, and that the treatment fits with your other medicines. GLP-1 supply has also been intermittent across Europe, which is worth knowing before you plan around it.

Weight management assessment and continuing treatment

Weight management treatment is assessed by a doctor through our online medical questionnaire, and the fee for that assessment is 29,90 €. There is no video consultation and no phone appointment: you complete a structured medical questionnaire, a doctor reviews it, and if continuation is appropriate you receive a prescription document by email as a PDF laid out to the Annex of Directive 2012/52/EU. You bring it to any pharmacy with photo identification. There is no PIN code and no national identity number on it. The fee covers the medical assessment, not the issuing of a document. If the doctor declines on medical or legal grounds, the fee is refunded. If the doctor asks you for documentation, you have at least 7 days to provide it and we will remind you before the deadline; if the consultation cannot be completed, we refund the full amount. The questionnaire asks for your height and weight, your waist measurement, your medical history including thyroid, pancreas and gallbladder problems, your other medicines and any previous weight-management treatment, and the doctor may ask for records from your own GP before deciding. A doctor who cannot establish that treatment is appropriate will decline, and that happens regularly with this group of medicines. Saxenda is not a shortcut around eating and activity changes; the licence itself ties it to a reduced-calorie diet and increased physical activity, and it works only alongside them.

Cost and reimbursement in Ireland

Weight management medicines are generally not reimbursed for obesity in Ireland, so most people pay the full pharmacy price for Saxenda, and it is expensive month after month. The Drugs Payment Scheme run by the HSE caps what a person or family pays for approved prescribed items in a calendar month, but whether a particular product is covered under a given scheme is a matter for the HSE reimbursement lists rather than for a general page, so check with your pharmacist and with the HSE before you budget. Ask the pharmacy what a month of treatment actually costs before you start, since this is a long-term treatment and stopping for cost reasons partway through usually means the weight returns. Prices, schemes and reimbursement decisions change over time.

Interactions and alcohol

Saxenda slows how quickly the stomach empties, which can change the absorption of medicines taken by mouth. In practice that rarely requires a change, but it matters for medicines with a narrow margin between effect and harm, and it is worth raising with your pharmacist. The interaction that needs planning is with diabetes treatment: combined with insulin or a sulfonylurea, liraglutide increases the risk of low blood sugar, so doses of those medicines are often reduced and monitoring increased. Liraglutide is not combined with another GLP-1 receptor agonist. Tell every prescriber and pharmacist that you use it. Alcohol is not directly contraindicated, but it adds calories, worsens nausea, and increases the risk of low blood sugar in anyone also on insulin or a sulfonylurea, so moderation is sensible.

Who should not use Saxenda

Saxenda is not for anyone with a known hypersensitivity to liraglutide or to any excipient in the pen. The product information sets out warnings that need weighing before treatment: a history of pancreatitis, gallbladder disease, severe gastrointestinal disease including severe gastroparesis, significant kidney or liver impairment, heart failure of advanced severity, and thyroid disease that you already have, because thyroid problems such as goitre were reported mainly in that group and the product information asks for caution there. Before any procedure under general anaesthesia or deep sedation, and before an endoscopy, tell the team that you use a GLP-1 medicine. Slower stomach emptying can leave food in the stomach despite the fasting you were told to follow, and that food can enter the lungs as anaesthesia is started. It is not used in pregnancy or breastfeeding. It is not a treatment for type 1 diabetes or for diabetic ketoacidosis. Anyone with a history of an eating disorder should have that discussed openly before treatment. The complete list is in the leaflet for the pen you hold.

Generic and brand names

Liraglutide is the international non-proprietary name of the active substance in Saxenda, which is the brand at the 3 mg daily dose for weight management. The same substance at lower daily doses is marketed under a different name for type 2 diabetes, and the two are not interchangeable, because the licensed indication, the target dose and the escalation differ. Liraglutide is not the same substance as semaglutide or tirzepatide, even though all act on GLP-1 pathways: the dosing intervals and the evidence differ, and a switch between them is a prescribing decision. A prescription written across borders states the international name with the strength and pharmaceutical form. Never accept a pen bought outside the pharmacy chain, whatever the label says, because falsified GLP-1 pens have circulated in Europe.

Pregnancy and breastfeeding

Saxenda must not be used during pregnancy. Weight loss offers no benefit to a developing pregnancy, and animal data raised concerns about harm to the foetus, so treatment is stopped if you become pregnant or plan to. Women who could become pregnant should use effective contraception during treatment and discuss timing with the prescriber if a pregnancy is planned. Unlike semaglutide and tirzepatide, the product information for liraglutide does not set a fixed interval here; treatment is simply stopped when a pregnancy is planned or occurs. It is not known whether liraglutide passes into human breast milk in significant amounts, and Saxenda should not be used while breastfeeding. If you discover you are pregnant while using it, stop the injections and contact your GP or maternity service for advice on nutrition and follow-up rather than simply continuing or panicking.

Patient information leaflet

The patient information leaflet inside the Saxenda carton is the authoritative document for the product you hold, and for an injectable it is more than a formality: it carries the step-by-step instructions for using the pen, attaching a needle, checking the flow and storing the pen before and after first use. It also lists the licensed indication, the dose escalation, the full side effect list with frequency categories and the warnings about pancreatitis and gallbladder disease. The HPRA publishes leaflets and summaries of product characteristics for medicines authorised in Ireland, and the European Medicines Agency publishes the assessment report for this centrally authorised product. Keep the leaflet for as long as you are in treatment, and follow it and your prescriber over anything you read online.

About this page

This page was written by the medical team at MEDINOW Sp. z o.o. and reviewed by lek. Damian Wojno, a doctor registered in Poland, PWZ no. 3211301. He holds a Polish licence to practise; he is not on the register of the Irish Medical Council, and this page does not suggest otherwise. Content verified on 29 August 2026 against the summary of product characteristics and the patient information leaflet published for the Irish market, and against public guidance from the HPRA and the HSE. This page is information, not advice for your particular case, and it is not an advertisement for a prescription medicine. Nothing here replaces an assessment by your own GP or a hospital clinician. If you are unwell and need urgent help, contact your GP, an out-of-hours service, or call 112 or 999.

Is Saxenda prescription-only in Ireland?

Yes. Saxenda is dispensed only against a valid prescription. Injectable GLP-1 pens offered by websites without a prescription are a known route for falsified products, and regulators including the HPRA have warned about them.

How long does Saxenda take to work?

Appetite usually changes within the first weeks, but the dose is increased gradually to 3.0 mg and the weight response is judged over months. The product information sets an expectation that treatment is reviewed and stopped if the weight response is inadequate, so this is not an open-ended prescription.

What are the common side effects of Saxenda?

Nausea, vomiting, diarrhoea, constipation, indigestion, abdominal pain, reduced appetite, headache, tiredness and injection site reactions are listed in the product information. Severe persistent abdominal pain spreading to the back needs urgent assessment, as it can indicate pancreatitis.

Can I drink alcohol while using Saxenda?

Alcohol is not directly contraindicated, but it adds calories, worsens nausea and raises the risk of low blood sugar for anyone also taking insulin or a sulfonylurea. Moderation is the sensible approach during treatment.

How do I request a weight management assessment for Saxenda?

You complete our online medical questionnaire and a doctor reviews it; the assessment costs 29,90 €. The fee covers the medical consultation, not the issuing of a document - the doctor decides after reviewing your form. If the doctor declines for medical or legal reasons, we refund the fee in full. If the doctor asks you for documentation, you have at least 7 days to provide it, and we will remind you before the deadline; if the consultation cannot be completed, we also refund the full amount. The doctor may request records from your own GP before deciding, and may decline.